Are you or your loved ones suffering from endometrial cancer?

You may be eligible to participate in a endometrial cancer clinical trial.

Are you or your loved ones suffering from endometrial cancer? You may be eligible to participate in a endometrial cancer clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Endometrial Cancer
NCT03099499 | Phase 2 | Interventional

Are you or your loved ones suffering from endometrial cancer?

You may be eligible to participate in a endometrial cancer clinical trial.

Are you or your loved ones suffering from endometrial cancer? You may be eligible to participate in a endometrial cancer clinical trial.

Recruiting

Female

18 +

years old

This study is looking to recruit 36 Participants

ONC201 is a small molecule which selectively targets the G protein-coupled receptor DRD2. Downstream of target engagement, ONC201 activates the integrated stress response (ISR) in tumor cell leading to inactivation of Akt and extracellular signal-regulated kinase (ERK) signaling as well as induction of the TRAIL pathway. ONC201 also inhibits dopamine receptor 2 (DRD2), resulting in anti-tumor responses in preclinical models. Single agent ONC201 has been examined in open-label Phase I studies in patients with advanced, treatment refractory solid malignancies. Due to its differential anti-proliferative and pro-apoptotic response in tumor cells, treatment was overall well tolerated, and the recommended phase II dose of ONC201 was set at 625mg every three weeks. An additional dose-escalation phase I study (NCT02609230) is further evaluating weekly versus three week dosing in patients with advanced solid tumors and multiple myeloma. Preliminary data from these phase I studies suggests a possible clinical benefit in patients with advanced, chemo-refractory endometrial cancers, with at least one mixed response noted in a patient with clear cell histology. Hypothesis: Single agent ONC201 will demonstrate clinical benefit in women with recurrent or metastatic endometrial cancers, especially in those women with alterations in the Phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of Rapamycin (mTOR) pathway.

Where you'll go

Selected location

Fox Chase Cancer Center

Fox Chase Cancer Center Change

333 Cottman Avenue, Philadelphia, PA, USA 19111

Gina Mantia-Smaldone, MD 215-214-1515

Map | Learn more
Interested in participating?
Selected location

Fox Chase Cancer Center

333 Cottman Avenue, Philadelphia, PA, USA 19111

Gina Mantia-Smaldone, MD 215-214-1515


The information you provide is confidential and is never sold or shared with outside vendors. By clicking the button, you agree to the PatientWing's Terms and Privacy Policy.
Sign up now